22.45
price down icon3.02%   -0.70
after-market After Hours: 22.95 0.50 +2.23%
loading
Liquidia Corp stock is traded at $22.45, with a volume of 2.77M. It is down -3.02% in the last 24 hours and down -1.54% over the past month. Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
See More
Previous Close:
$23.15
Open:
$23.3
24h Volume:
2.77M
Relative Volume:
1.03
Market Cap:
$1.93B
Revenue:
$19.32M
Net Income/Loss:
$-141.47M
P/E Ratio:
-13.32
EPS:
-1.6851
Net Cash Flow:
$-120.48M
1W Performance:
+0.49%
1M Performance:
-1.54%
6M Performance:
+66.17%
1Y Performance:
+103.35%
1-Day Range:
Value
$22.05
$23.94
1-Week Range:
Value
$21.94
$24.38
52-Week Range:
Value
$9.71
$29.94

Liquidia Corp Stock (LQDA) Company Profile

Name
Name
Liquidia Corp
Name
Phone
919.328.4400
Name
Address
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
Name
Employee
170
Name
Twitter
@Liquidia_Inc
Name
Next Earnings Date
2025-03-19
Name
Latest SEC Filings
Name
LQDA's Discussions on Twitter

Compare LQDA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
LQDA
Liquidia Corp
22.45 1.99B 19.32M -141.47M -120.48M -1.6851
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
417.21 108.30B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
652.91 69.37B 14.25B 4.58B 3.56B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.59 62.38B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
821.97 51.50B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.95 34.94B 398.11M -1.03B -868.57M -5.7032

Liquidia Corp Stock (LQDA) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-20-25 Initiated Wells Fargo Overweight
Aug-15-25 Resumed Jefferies Buy
May-19-25 Downgrade Oppenheimer Perform → Underperform
Dec-20-24 Initiated Wells Fargo Overweight
Oct-16-24 Initiated Scotiabank Sector Outperform
Aug-19-24 Upgrade Raymond James Outperform → Strong Buy
Aug-16-24 Initiated Raymond James Outperform
Jun-25-24 Initiated Oppenheimer Perform
Jan-05-24 Reiterated Needham Buy
Sep-19-22 Resumed Wedbush Underperform
Sep-01-22 Downgrade Wedbush Neutral → Underperform
Jul-22-22 Initiated Ladenburg Thalmann Buy
May-31-22 Initiated BTIG Research Buy
May-26-22 Initiated BofA Securities Buy
Dec-04-20 Initiated H.C. Wainwright Buy
Nov-20-20 Downgrade Wedbush Outperform → Neutral
Nov-08-18 Resumed Jefferies Buy
Sep-05-18 Initiated Wedbush Outperform
Aug-20-18 Initiated Jefferies Buy
Aug-20-18 Initiated Needham Buy
View All

Liquidia Corp Stock (LQDA) Latest News

pulisher
Oct 29, 2025

Has Liquidia Corporation formed a bullish divergence2025 Bull vs Bear & Momentum Based Trading Signals - newser.com

Oct 29, 2025
pulisher
Oct 28, 2025

What sentiment indicators say about Liquidia Corporation stockEarnings Overview Summary & Stock Portfolio Risk Management - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Will Liquidia Corporation (LT4) stock profit from automation waveJuly 2025 Intraday Action & Community Consensus Stock Picks - newser.com

Oct 28, 2025
pulisher
Oct 28, 2025

Is Liquidia Corporation showing signs of accumulationJuly 2025 PreEarnings & Real-Time Price Movement Reports - newser.com

Oct 28, 2025
pulisher
Oct 27, 2025

What dividend safety rating applies to Liquidia Corporation (LT4) stockMarket Growth Summary & Real-Time Sentiment Analysis - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will Liquidia Corporation stock keep outperforming rivals2025 Price Targets & Safe Entry Zone Tips - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will Liquidia Corporation stock attract more institutional investorsBuy Signal & Accurate Entry/Exit Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025 - Quiver Quantitative

Oct 27, 2025
pulisher
Oct 27, 2025

How Liquidia Corporation stock performs in stagflationPortfolio Growth Summary & Intraday High Probability Setup Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Will Liquidia Corporation (LT4) stock sustain uptrend momentumEntry Point & Stepwise Trade Signal Implementation - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Does Liquidia Corporation show high probability of reboundPortfolio Update Summary & Long-Term Safe Investment Plans - newser.com

Oct 27, 2025
pulisher
Oct 26, 2025

Liquidia's (LQDA) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat

Oct 26, 2025
pulisher
Oct 23, 2025

Applying sector rotation models to Liquidia CorporationQuarterly Portfolio Review & Advanced Swing Trade Entry Plans - newser.com

Oct 23, 2025
pulisher
Oct 21, 2025

Wall Street Analysts Believe LIQUIDIA CORP (LQDA) Could Rally 50.94%: Here's is How to Trade - sharewise.com

Oct 21, 2025
pulisher
Oct 21, 2025

Liquidia Corporation (LQDA) Stock Analysis: Exploring a 50.94% Potential Upside in a Booming Biotechnology Sector - DirectorsTalk Interviews

Oct 21, 2025
pulisher
Oct 21, 2025

Liquidia Corp: Shares Remain Mispriced Despite Yutrepia's Exceptional Commercial Launch - Seeking Alpha

Oct 21, 2025
pulisher
Oct 19, 2025

Is Liquidia Corporation (LT4) stock a top dividend aristocrat candidate2025 Top Gainers & Safe Entry Trade Reports - nchmf.gov.vn

Oct 19, 2025

Liquidia Corp Stock (LQDA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$36.67
price up icon 0.71%
$90.18
price down icon 1.60%
$28.95
price down icon 0.62%
$103.35
price down icon 1.60%
biotechnology ONC
$314.85
price down icon 0.63%
$166.95
price up icon 1.00%
Cap:     |  Volume (24h):